HC Wainwright & Co. Reiterates Buy on Protalix BioTherapeutics, Maintains $10 Price Target

11/14/23 6:50:25 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Protalix BioTherapeutics (AMEX:PLX) with a Buy and maintains $10 price target.

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PLX

Date	Price Target	Rating	Analyst